Mikhail Blagosklonny is a research scientist, philanthropist and university professor. He has previously stated that he hopes that he will someday be able to ensure that all the people of the world will have easy access to the very best medical treatment currently available regardless of the state of their personal finances. His special interest is in the area of medical research.
Cancer And Aging
Blagosklonny is concerned with studying cancer and aging. He is particularly interested in the connection between the two. He is striving to learn just why cancer is more frequent among grown adults who are over a certain age. He has come up with a hypothesis concerning the potential part TOR signaling has in cancer and aging. He proposes that rapamycin, a well-known cancer drug as one potential treatment for extending life. This is just one reason why some consider Mikhail Blagosklonny to be one of the most ardent advocates for rapamycin in the area of longevity research.
His Current Research
At present, he is conducting research that he thinks will continue to be of use in the oncology field. He also has a continued influence on other as a university professor, a researcher and as a known expert in his field. He is also reported by various sources to be a font of inspiration to both is peers and to all his students who hope to someday further expand on his research one day in the future.
Specific Areas Of Interest
Blagosklonny’s specific subjects of interest within the overall field of cancer and aging have brought him quite a lot of attention from others in the field of medicine. His overall mission is to not just to learn how to treat cancer but to treat it in a way that is painless, effective and notably less expensive when compared to the various methods used to treat cancer today. He is working hard to learn how to destroy cancerous cells inside a patient’s body without eliminating any of the normal, thriving, healthy cells that are important to the general healing of the mind and body after the numerous months or even years of cancer treatment.
As this piece goes to press, Blagosklonny has already made a lot of progress in his specific areas of interest. He also hopes that the discoveries he has made will continue to serve as a source of inspiration and encouragement to others around the world and that these same people will one day follow in his professional footsteps and pick up where he will someday leave off. Blagosklonny believes that eventually, in the future, the treatment of cancer will not be just a luxury for patients with enough money, but will actually be simple, inexpensive and available to anyone who needs it.
Editorial Interests And Activities
Mikhail Blagosklonny is also the co-editor-in-chief of Oncotarget, Aging, and Cell Cycle. Blagosklonny is also the associate editor of Cancer Biology & Therapy and sits on the editorial board of Cell Death & Differentiation.